Hereditary or sporadic polyposis syndromes.
Basso G
Best Pract Res Clin Gastroenterol. 2017 Jun 6;31(4):409-417. doi: 10.1016/j.bpg.2017.05.011
Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer.
Malesci A
Oncoimmunology. 2017 Jul 12;6(12):e1342918. doi: 10.1080/2162402X.2017.1342918
Evolving notions on immune response in colorectal cancer and their implications for biomarker development.
Grizzi F
Inflamm Res. 2018 Jan 10;67(5):375-389. doi: 10.1007/s00011-017-1128-1
Protumor Steering of Cancer Inflammation by p50 NF-κB Enhances Colorectal Cancer Progression.
Porta C
Cancer Immunol Res. 2018 Mar 27;6(5):578-593. doi: 10.1158/2326-6066.CIR-17-0036
Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry.
Paiella S
Am J Gastroenterol. 114(4):665-670. doi: 10.1038/s41395-018-0414-z
Combined Low Densities of FoxP3(+) and CD3(+) Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression.
Cavalleri T
Cancer Immunol Res. 2019 Feb 25;7(5):751-758. doi: 10.1158/2326-6066.CIR-18-0661
ERK-dependent downregulation of the atypical chemokine receptor D6 drives tumor aggressiveness in Kaposi sarcoma.
Savino B
Cancer Immunol Res. 2014 Apr 2;2(7):679-89. doi: 10.1158/2326-6066.CIR-13-0202
Atypical matters in myeloid differentiation.
Locati M, Mantovani A, Bonecchi R
Nat Immunol. 18(7):711-712. doi: 10.1038/ni.3776
Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy.
Mollica Poeta V
Front Immunol. 2019 Mar 6;10:379. doi: 10.3389/fimmu.2019.00379
One Clever Macrophage Checkpoint.
Mantovani A, Bonecchi R
Clin Cancer Res. 2019 Apr 1;25(11):3202-3204. doi: 10.1158/1078-0432.CCR-19-0483